Soy phytoestrogens: efficiency in menopause and potential side effects
Keywords:phytoestrogens, soy, menopause, diet
Phytoestrogens are present in certain edible plants being most abundant in soy; they are structurally and functionally analogous to estrogens. These substances are used for compensation of hormone deficiency in menopause. Some recent reviews concluded that there is no convincing evidence in favor of relieving menopausal symptoms by phytoestrogens compared to placebo. Soy is used as ingredient of infant food and other foodstuffs as well as animal fodder, so that residual phytoestrogens and their active metabolites such as equol can remain in meat products. Soy protein is broadly used by the food industry. Derangements of the reproductive system in humans under the impact of phytoesthrogens are regarded to be rare and mild. There have been singular reports on modified gender-related behavior in children and feminization in consequence of abundant soy consumption. In animals, the intake of phytoestrogens was reported to impact fertility, sexual development and behavior. Phytoestrogens are named disruptors or selective modulators of the endocrine system. There are no reasons to assume that beneficial effects of such modulation would overweigh harm in all soy consumers. Feminizing effects in humans may be subtle but statistically significant in large populations. The literature on phytoestrogens is extensive; many authors recommend their practical use. However, in recent reviews, it was concluded about insufficient evidence on the effectiveness of phytoestrogens as a means for replacement therapy during menopause. Side effects of phytoestrogens have also been reported. There are fears that mass consumption of soybeans by a population not adapted to it may have a feminizing effect. Objective studies of a high quality level, including animal experiments, are needed to document endocrine effects.
Plotnikova TM, Anishchenko AM, Plotnikov MB. Phytoestrogens: mechanisms of correction of cardiovascular complications of climacteric syndrome. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2017;80(1):39-44. doi:10.30906/0869-2092-2017-80-1-39-44. (in Russian).
Selyukova NYu, Karpenko NO, Koreneva EM, et al. The impact of male phytoestrogenization on the somato-sexual development and fertility of the offsprings in rats. Fiziologichnyi Zhurnal. 2014;60(2):82-87. (in Ukrainian).
Latendresse JR, Bucci TJ, Olson G, et al. Genistein and ethinyl estradiol dietary exposure in multigenerational and chronic studies induce similar proliferative lesions in mammary gland of male Sprague-Dawley rats. Reprod Toxicol. 2009;28(3):342-353. doi:10.1016/j.reprotox.2009.04.006.
Hashem NM, Abo-Elsoud MA, Nour El-Din ANM, Kamel KI, Hassan GA. Prolonged exposure of dietary phytoestrogens on semen characteristics and reproductive performance of rabbit bucks. Domest Anim Endocrinol. 2018;64:84-92. doi:10.1016/j.domaniend.2018.03.003.
Jacobsen BK, Jaceldo-Siegl K, Knutsen SF, Fan J, Oda K, Fraser GE. Soy isoflavone intake and the likelihood of ever becoming a mother: the Adventist Health Study-2. Int J Womens Health. 2014;6:377-384. doi:10.2147/IJWH.S57137.
Thelen P, Wuttke W, Seidlová-Wuttke D. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer. J Steroid Biochem Mol Biol. 2014;139:290-293. doi:10.1016/j.jsbmb.2013.06.009.
Dean M, Murphy BT, Burdette JE. Phytosteroids beyond estrogens: Regulators of reproductive and endocrine function in natural products. Mol Cell Endocrinol. 2017;442:98-105. doi:10.1016/j.mce.2016.12.013.
Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause. 2012;19(7):776-790. doi:10.1097/gme.0b013e3182410159.
Gold EB, Leung K, Crawford SL, Huang MH, Waetjen LE, Greendale GA. Phytoestrogen and fiber intakes in relation to incident vasomotor symptoms: results from the Study of Women's Health Across the Nation. Menopause. 2013;20(3):305-314. doi:10.1097/GME.0b013e31826d2f43.
Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007;(4):CD001395. doi:10.1002/14651858.CD001395.pub3.
Guidozzi F, Alperstein A, Bagratee JS, et al. South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014. S Afr Med J. 2014;104(8):537-543. doi:10.7196/samj.8423.
Ye CF, Pan YM, Zhou H. Regulation of vitamin D receptor and Genistein on bone metabolism in mouse osteoblasts and the molecular mechanism of osteoporosis. J Biol Regul Homeost Agents. 2018;32(3):497-505.
Arcoraci V, Atteritano M, Squadrito F, et al. Antiosteoporotic Activity of Genistein Aglycone in Postmenopausal Women: Evidence from a Post-Hoc Analysis of a Multicenter Randomized Controlled Trial. Nutrients. 2017;9(2):179. doi:10.3390/nu9020179.
This P, de Cremoux P, Leclercq G, Jacquot Y. A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas. 2011;70(3):222-226. doi:10.1016/j.maturitas.2011.07.001.
Leclercq G, de Cremoux P, This P, Jacquot Y. Lack of sufficient information on the specificity and selectivity of commercial phytoestrogens preparations for therapeutic purposes. Maturitas. 2011;68(1):56-64. doi:10.1016/j.maturitas.2010.10.003.
Viggiani MT, Polimeno L, Di Leo A, Barone M. Phytoestrogens: Dietary Intake, Bioavailability, and Protective Mechanisms against Colorectal Neoproliferative Lesions. Nutrients. 2019;11(8):1709. doi:10.3390/nu11081709.
Orekhov AN, Sobenin IA, Revin VV, Bobryshev YV. Development of Antiatherosclerotic Drugs on the basis of Natural Products Using Cell Model Approach. Oxid Med Cell Longev. 2015;2015:463797. doi:10.1155/2015/463797.
De Dios ST, Frontanilla KV, Nigro J, et al. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J Diabetes Complications. 2007;21(2):108-117. doi:10.1016/j.jdiacomp.2006.03.003.
Drzewoski J, Zurawska-Klis M. Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. Curr Med Res Opin. 2006;22(10):1921-1926. doi:10.1185/030079906X132424.
How to Cite
Copyright (c) 2020 S.V. Jargin
This work is licensed under a Creative Commons Attribution 4.0 International License.